TY - JOUR
T1 - Burden and rates of treatment and contr of cardiovascular disease risk factors in obesity
T2 - the framingham heart study
AU - Molenaar, Esther A.
AU - Hwang, Shih Jen
AU - Vasan, Ramachandran S.
AU - Grobbee, Diederick E.
AU - Meigs, James B.
AU - D'Agostino, Ralph B.
AU - Levy, Daniel
AU - Fox, Caroline S.
PY - 2008/7
Y1 - 2008/7
N2 - OBJECTIVE - Obesity is associated with an increased risk for cardiovascular disease (CVD). We sought to determine rates of treatment and control of CVD risk factors among normal weight, overweight, and obese individuals in a community-based cohort. RESEARCH DESIGN AND METHODS - Participants free of CVD (n = 6,801; mean age 49 years; 54% women) from the Framingham Offspring and Third Generation cohorts who attended the seventh Offspring examination (1998-2001) or first Third Generation (2002-2005) examination were studied. RESULTS - Obese participants with hypertension were more likely to receive antihyperten- sive treatment (62.3%) than normal weight (58.7%) or overweight (59.0%) individuals (P = 0.002), but no differences in hypertension control across BMI subgroups among participants with hypertension were observed (36.7% [normal weight], 37.3% [overweight], and 39.4% [obese]; P = 0.48). Rates of lipid-lowering treatment were higheramong obese participants with elevated LDL cholesterol (39.5%) compared with normal weight (34.2%) or overweight (36.4%) participants (P = 0.02), but control rates among those with elevated LDL cholesterol did not differ across BMI categories (26.7% [normal weight], 26.0% [overweight], and 29.2% [obese]; P = 0.11). There were no differences in diabetes treatment among participants with diabetes across BMI groups (69.2% [normal weight], 50.0% [overweight], 55.0% [obese]; P = 0.54), but obese participants with diabetes were less likely to have fasting blood glucose <126 mg/dl (15.7%) compared with normal weight (30.4%) or overweight (20.7%) participants (P = 0.02). CONCLUSIONS - These findings emphasize the suboptimal rates of treatment and control of CVD risk factors among overweight and obese individuals.
AB - OBJECTIVE - Obesity is associated with an increased risk for cardiovascular disease (CVD). We sought to determine rates of treatment and control of CVD risk factors among normal weight, overweight, and obese individuals in a community-based cohort. RESEARCH DESIGN AND METHODS - Participants free of CVD (n = 6,801; mean age 49 years; 54% women) from the Framingham Offspring and Third Generation cohorts who attended the seventh Offspring examination (1998-2001) or first Third Generation (2002-2005) examination were studied. RESULTS - Obese participants with hypertension were more likely to receive antihyperten- sive treatment (62.3%) than normal weight (58.7%) or overweight (59.0%) individuals (P = 0.002), but no differences in hypertension control across BMI subgroups among participants with hypertension were observed (36.7% [normal weight], 37.3% [overweight], and 39.4% [obese]; P = 0.48). Rates of lipid-lowering treatment were higheramong obese participants with elevated LDL cholesterol (39.5%) compared with normal weight (34.2%) or overweight (36.4%) participants (P = 0.02), but control rates among those with elevated LDL cholesterol did not differ across BMI categories (26.7% [normal weight], 26.0% [overweight], and 29.2% [obese]; P = 0.11). There were no differences in diabetes treatment among participants with diabetes across BMI groups (69.2% [normal weight], 50.0% [overweight], 55.0% [obese]; P = 0.54), but obese participants with diabetes were less likely to have fasting blood glucose <126 mg/dl (15.7%) compared with normal weight (30.4%) or overweight (20.7%) participants (P = 0.02). CONCLUSIONS - These findings emphasize the suboptimal rates of treatment and control of CVD risk factors among overweight and obese individuals.
UR - http://www.scopus.com/inward/record.url?scp=49649115284&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=49649115284&partnerID=8YFLogxK
U2 - 10.2337/dc07-2413
DO - 10.2337/dc07-2413
M3 - Article
C2 - 18375414
AN - SCOPUS:49649115284
SN - 0149-5992
VL - 31
SP - 1367
EP - 1372
JO - Diabetes care
JF - Diabetes care
IS - 7
ER -